Subscribe

Distinctions and Parallels Among TRK Inhibitors

Interview with the Innovators
Videos

Featuring:

Ezra Cohen, MD, FRCPSC, FASCO
Professor of Medicine
Chief
Division of Hematology/Oncology
UC San Diego
La Jolla, CA
Mary Jo Fidler, MD
Associate Professor and Section Chief
Medical Oncology
Rush University Medical Center
Chicago, IL
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Enterprise Medical Director of Research
Comprehensive Care and Research Center
Philadelphia, PA
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors.

Related Articles

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Interview with the Innovators
Videos
Read Article
Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Interview with the Innovators
Videos
Read Article
Broadening the Variety of Candidate Therapies for R/R Follicular Lymphoma Allows Optimal Personalized Rx Choice, While Patient-Directed Education Helps Attain Greatest Clinical Benefit
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Interview with the Innovators
Videos
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

© Amplity Health. All Rights Reserved. Privacy Policy.